W"hile this is our first formal partnership; we areconfident and optimistic there are other highvalue opportunities for iSonea in the near term."I believe the term is "stay tuned."Reads very well. 4's to go this arvo?
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status